modified-dendritic cell vaccine

This autologous modified-dendritic cell (DC) vaccine is an experimental immunotherapy developed for the treatment of resected non-small cell lung cancer (NSCLC). The vaccine is generated from patient-derived peripheral blood mononuclear cells that are differentiated into dendritic cells and subsequently modified to enhance their immunostimulatory capacity. Specifically, the DCs are pulsed with two tumor-associated antigens, survivin and Mucin-1 (MUC1), to direct the immune response against cancer cells. To overcome immune suppression, the cells are treated with siRNA to silence the Suppressor of Cytokine Signaling 1 (SOCS1), a negative regulator of DC activation. Furthermore, the vaccine is stimulated with flagellin, a Toll-like receptor 5 (TLR5) agonist, which promotes DC maturation and the secretion of pro-inflammatory cytokines such as IL-6 and TNF-α. This multi-antigen, checkpoint-silenced, and TLR-stimulated approach is designed to break self-tolerance and elicit robust cytotoxic T-lymphocyte responses to prevent tumor recurrence.

Other names

survivin and MUC1 pulsed DC vaccine silenced with SOCS1 and stimulated with flagellinautologous modified-DC vaccine